Wednesday, December 12, 2018 -- MedicalResearch.comInterview with: Zhaohui Gu, PhDPostdoctoral Research Associate St. Jude Children’s Research Hospital, TN MedicalResearch.com: What is the background for this study? What are the main findings? Response:B-progenitor acute lymphoblastic leukemia (B-ALL) is the most common pediatric malignancy and the leading cause of … Continue reading →
Thursday, December 13, 2018 -- Traditionally, hematopoietic stem cell transplantation (HSCT) from both HLA-matched related and unrelated donors (UD) has been used for treating children with acute leukemia (AL) in need of an allograft. Recently, HLA-haploidentical HSCT after αβ T-cell/B-cell depletion (αβhaplo-HSCT) was shown to be effective in single-center studies. Here, we report the first multicenter retrospective analysis of 127 matched UD (MUD), 118 mismatched UD (MMUD), and 98 αβhaplo-HSCT recipients, transplanted between 2010 and 2015, in 13 Italian centers. All these AL children were transplanted in morphological remission after a myeloablative conditioning regimen. Graft failure occurred in 2% each of UD-HSCT and αβhaplo-HSCT groups. In MUD vs MMUD-HSCT recipients, the cumulative incidence of grade II to IV and grade III to IV acute
Wednesday, December 12, 2018 -- For the second straight year, AstraZeneca is spending the fall launching a hemo-oncology drug. Lumoxiti, a treatment for the rare disease hairy cell leukemia, is rolling out to patients after a Sept. 14 FDA approval, with AZ initially targeting 10-15 high-priority clinics.